EA202090250A1 - IMPROVED DOUBLE SPECIFICITY POLYPEPTIDE MOLECULE - Google Patents

IMPROVED DOUBLE SPECIFICITY POLYPEPTIDE MOLECULE

Info

Publication number
EA202090250A1
EA202090250A1 EA202090250A EA202090250A EA202090250A1 EA 202090250 A1 EA202090250 A1 EA 202090250A1 EA 202090250 A EA202090250 A EA 202090250A EA 202090250 A EA202090250 A EA 202090250A EA 202090250 A1 EA202090250 A1 EA 202090250A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptide molecule
improved double
double specificity
specificity polypeptide
binding region
Prior art date
Application number
EA202090250A
Other languages
Russian (ru)
Inventor
Мартин Хофманн
Феликс Унвердорбен
Себастиан Бунк
Доминик Маурер
Original Assignee
Имматикс Байотекнолоджиз Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Имматикс Байотекнолоджиз Гмбх filed Critical Имматикс Байотекнолоджиз Гмбх
Priority claimed from PCT/EP2018/069151 external-priority patent/WO2019012138A1/en
Publication of EA202090250A1 publication Critical patent/EA202090250A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к биспецифической молекуле полипептида, содержащей первую полипептидную цепь и вторую полипептидную цепь, обеспечивающие связывающий участок, полученный из Т-клеточного рецептора (ТКР), специфичного к пептидному эпитопу, ассоциированному с главным комплексом гистосовместимости (МНС), и связывающий участок, полученный из антитела, способного к привлечению иммунных эффекторных клеток человека за счет специфического связывания с поверхностным антигеном указанных клеток, а также к способам получения биспецифической молекулы полипептида и их применению.The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T-cell receptor (TCR) specific for a peptide epitope associated with a major histocompatibility complex (MHC) and a binding region obtained from an antibody capable of attracting human immune effector cells through specific binding to the surface antigen of these cells, as well as to methods for producing a bispecific polypeptide molecule and their use.

EA202090250A 2018-04-16 2018-07-13 IMPROVED DOUBLE SPECIFICITY POLYPEPTIDE MOLECULE EA202090250A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862658318P 2018-04-16 2018-04-16
PCT/EP2018/069151 WO2019012138A1 (en) 2017-07-14 2018-07-13 Improved dual specificity polypeptide molecule

Publications (1)

Publication Number Publication Date
EA202090250A1 true EA202090250A1 (en) 2020-05-08

Family

ID=70847669

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202090240A EA202090240A1 (en) 2018-04-16 2018-07-13 IMPROVED DOUBLE SPECIFICITY POLYPEPTIDE MOLECULE
EA202090250A EA202090250A1 (en) 2018-04-16 2018-07-13 IMPROVED DOUBLE SPECIFICITY POLYPEPTIDE MOLECULE

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA202090240A EA202090240A1 (en) 2018-04-16 2018-07-13 IMPROVED DOUBLE SPECIFICITY POLYPEPTIDE MOLECULE

Country Status (1)

Country Link
EA (2) EA202090240A1 (en)

Also Published As

Publication number Publication date
EA202090240A1 (en) 2020-05-08

Similar Documents

Publication Publication Date Title
MX2020011744A (en) Improved dual specificity polypeptide molecule.
DOP2023000165A (en) CD3 BINDING ANTIBODIES
EA201991577A1 (en) NEW ANTIBODIES AGAINST THE HUMAN TRANSFERRIN RECEPTOR, ABLE TO BREAK THE HEMATOENCEPHALIC BARRIER
CO2020006905A2 (en) New genetically modified T-cell receptors and immune therapies using them
EA201990171A1 (en) SPECIFIC ANTIBODY AGAINST EGFR AND AGAINST CD3 AND ITS APPLICATION
CL2023000562A1 (en) Antigen-binding proteins that specifically bind mage-a
RU2016151235A (en) ANTIBODIES CONTACTING CD3 HUMAN EPSILON AND MONKEY ZINOMOLGUS
PE20210517A1 (en) ANTI-HLA-G ANTIBODIES AND THE USE OF THEM
PE20091196A1 (en) ANTIBODIES AGAINST COMPLETELY HUMAN VEGF, COMPOSITIONS AND METHODS
AU2015287227A8 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
PH12020551153A1 (en) Antibodies specific for cd70 and their uses
EA201590187A1 (en) MONOCLONAL ANTIBODIES FOR THE APPLICATION IN DIAGNOSTICS AND THERAPY OF MALIGNANT TUMORS AND AUTOIMMUNE DISEASE
EA202091569A1 (en) MONOCLONAL ANTIBODIES AND METHODS OF THEIR APPLICATION
AR112228A1 (en) POLYPEPTIDE MOLECULE WITH ENHANCED DUAL SPECIFICITY
CL2021001704A1 (en) Monoclonal antibodies that specifically bind to the beta region of the human t-cell receptor trbv-9 family, and methods for their use.
MX2023005313A (en) Fcrn antibodies and methods of use thereof.
RU2017124512A (en) METHOD FOR DETERMINING ANTIBODIES CAUSING COMPLEMENT-DEPENDENT CYTOTOXICITY
CO2021009689A2 (en) Monoclonal antibodies that specifically bind to the beta region of the trbv-9 family of the human T cell receptor, and methods for their use.
MX2022005949A (en) Anti-ror-2 antibodies and methods of use.
MX2022001380A (en) Fcrn antibodies and methods of use thereof.
EA202090250A1 (en) IMPROVED DOUBLE SPECIFICITY POLYPEPTIDE MOLECULE
PH12020500098A1 (en) Improved dual specific polypeptide molecule
AR107083A1 (en) ANTIBODIES DIRECTED TO CD32B AND METHODS OF USE OF THE SAME
WO2021016534A3 (en) Antigenic polypeptides and methods of use thereof
EA201992002A1 (en) T-CELL RECEPTORS AND IMMUNE THERAPY OF PRAME-POSITIVE CANCER DISEASES WITH THEIR APPLICATION